Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies

Risultati finali

2nd iteration to characterize molecular mechanism leading to irAEs

2nd iteration of the characterizing molecular mechanisms of irAEs.

1st iteration to characterize molecular mechanism leading to irAEs

A data catalogue of analysed and interpreted high throughput molecular profiling datasets to reveal molecular mechanism leading to irAEs. The exact modelling methods will be based upon the type of profiling data generated in Task 4.2. and the criteria established in the analysis plans.

Preliminary irAOP - CPI Mo

Same as D2.1, but for Checkpoint inhibitors

1st iteration refined hepatoxicity in vivo models

This will be a set of models that have been initially refined based upon the outcome of the imSAVAR workshop on Checkpoint inhibitor MoA. This will be a report that defines the refinements and describes and confirmatory work that has been done.

CPI immune safety assessment research roadmap

Same as D23 but for Checkpoint inhibitors

2nd iteration in vitro & MPS models

This is a second iteration of D2.5 which will include further refinements and possibly new models

CAR-T & BITE immune safety assessment research roadmap

A document that is based upon the outcome of the imSAVAR workshops on CAR-T/BiTE immune safety assessment. It will contain a description of the highest priority irAOPs for CAR-T/BiTE MoAs, input from different stakeholders including regulators. This document will also highlight the most important areas where further research and development is needed with specific representation of what is planned for the effort in imSAVAR

1st iteration in vivo and in vitro models IL-2 Moa

This will be a set of refined in vivo models and in vitro that have been initially refined based upon the outcome of the imSAVAR workshop on IL2 MoA This will be a report that defines the refinements and describes and confirmatory work that has been done

Dissemination materials

A websiste, overview, slides, and a dynamic set of messages for use in describing and disseminating the outputs of imSAVAR and for building the stakeholder community.

TReg-IL2 immune safety assessment research roadmap

A document that is based upon the outcome of the imSAVAR workshop on TR-IL2 MoA. It will contain a description of the highest priority irAOPs for TR-IL2 MoA, and the input from different stakeholders including regulators. This document will also highlight the most important areas where further research and development is needed with specific representation of what is planned for the effort in imSAVAR

Preliminary irAOP - CAR-T & BiTE MoAs

In order to inform the attendees for the workshop and to form the basis for the assessment roadmap the preliminary irAOPs will be pathways of the most different adverse outcomes for CAR-T and BiTEs. These will be defined by the consortium members and supplemented by research and available data where possible.

Preliminary irAOP - IL2-TREG

In order to inform the attendees for the workshop and to from the basis for the assessment roadmap the preliminary irAOPs will be pathways of the most different adverse outcomes for IL2-TREG MoA. These will be define by the consortium members and supplemented by research and available data where possible.

1st iteration refined in vivo & in vitro model readouts IL-2 MoA

This will be a set of improved model readouts that have been initially refined based upon the outcome of the imSAVAR workshop on IL 2 MoA This will be a report that defines the refinements and describes and confirmatory work that has been done

3rd imSAVAR workshop

Same as 13 but for IL2 Treg MoA

1st imSAVAR workshop

This workshop will be multi-stakeholder, multi-disciplinary workshop to define irAOPs specific case study for CAR-T cells and CD3-targeted bispecific antibodies. Within this workshop the gaps for where models need to be refined or new models developed.

1st iteration in vitro & MPS models

This will be a set of models that have been initially refined based upon the outcome of the imSAVAR workshops on the different in vitro MPSs models developed to address the gaps in the irAOPs This will be a report that defines the refinements and describes and confirmatory work that has been done

Distributed network biobanking system

A system the process of know which types of samples are available where and support the process of accessing them.

Network of disease domain providers for providing samples

A defined network of centres and defined processes for accessing samples taking into consideration ethics and data privacy concerns. The report on this deliverable will include a description of how this network was used in during the implementation of imSAVAR

1st iteration of advanced immune cell profiling

A dataset of high throughput molecular profiling datasets. The exact molecular profiling techniques will be based upon the outcomes of the workshops, the progress in model, development, and the criteria established in the analysis plans. This will have undergone initial bioinformatic processings to produce a dataset that is useful for identifying biomarkers as well as mechanistic insights from the models being refined and developed in imSAVAR.

2nd iteration of advanced immune cell profiling

2nd iteration of the molecular profiling datasets.

Pubblicazioni

A time-resolved meta-analysis of consensus gene expression profiles during human T-cell activation

Autori: Michael Rade; Sebastian Böhlen; Vanessa Neuhaus; Dennis Löffler; Conny Blumert; Maximilian Merz; Ulrike Köhl; Susann Dehmel; Katherina Sewald; Kristin Reiche
Pubblicato in: Genome Biology, 2023, ISSN 1474-760X
Editore: Springer Nature
DOI: 10.1186/s13059-023-03120-7

Immunocompetent cancer-on-chip models to assess immuno-oncology therapy

Autori: Maulana, Tengku Ibrahim; Kromidas, Elena; Wallstabe, Lars; Cipriano, Madalena; Alb, Miriam; Zaupa, Cécile; Hudecek, Michael; Fogal, Birgit; Loskill, Peter
Pubblicato in: Advanced Drug Delivery Reviews, 2021, Pagina/e 281-305, ISSN 0169-409X
Editore: Elsevier BV
DOI: 10.1016/j.addr.2021.03.015

A Spatial Transcriptomics Browser for Discovering Gene Expression Landscapes across Microscopic Tissue Sections

Autori: Maria Schmidt; Susanna Avagyan; Kristin Reiche; Hans Binder; Henry Loeffler-Wirth
Pubblicato in: Current Numeros in Molecular Biology, 2024, ISSN 1467-3037
Editore: Caister Academic Press
DOI: 10.3390/cimb46050284

Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells

Autori: Tengku Ibrahim Maulana; Claudia Teufel; Julia Roosz; Lisa Lazarevski; Francijna E. van den Hil; Lukas Scheller; Valeria Orlova; André Koch; Michael Hudecek; Miriam Alb; Peter Loskill
Pubblicato in: Cell Stem Cell, Numero Cell Press, 2024, ISSN 1934-5909
Editore: Cell Press
DOI: 10.1016/j.stem.2024.04.018

Immuno-inflammatory in vitro hepatotoxicity models to assess side effects of biologicals exemplified by aldesleukin

Autori: Luise A. Roser; Sonja Luckhardt; Nicole Ziegler; Dominique Thomas; Pia Viktoria Wagner; Georg Damm; Andrea Scheffschick; Philip Hewitt; Michael J. Parnham;Susanne Schiffmann
Pubblicato in: Frontiers in Immunology, 2023, ISSN 1664-3224
Editore: Frontiers Media SA
DOI: 10.3389/fimmu.2023.1275368

Transcriptional states of CAR-T infusion relate to neurotoxicity – lessons from high-resolution single-cell SOM expression portraying

Autori: Henry Loeffler-Wirth, Michael Rade, Arsen Arakelyan, Markus Kreuz, Markus Loeffler, Ulrike Koehl, Kristin Reiche, and Hans Binder
Pubblicato in: Frontiers in Immunology, 2022, ISSN 1664-3224
Editore: Frontiers Media SA
DOI: 10.3389/fimmu.2022.994885

Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival

Autori: Ziena Abdulrahman; Saskia J Santegoets; Gregor Sturm; Pornpimol Charoentong; Marieke E Ijsselsteijn; Antonios Somarakis; Thomas Höllt; Francesca Finotello; Zlatko Trajanoski; Sylvia L van Egmond; Dana A M Mustafa; Marij J P Welters; Noel F C C de Miranda; Sjoerd H van der Burg
Pubblicato in: Journal for ImmunoTherapy of Cancer, 2022, ISSN 2051-1426
Editore: Society for Immunotherapy of Cancer
DOI: 10.1136/jitc-2021-004346

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies.

Autori: Xiang Zhou; Leo Rasche; K. Martin Kortüm; Sophia Danhof; Michael Hudecek; Hermann Einsele
Pubblicato in: Frontiers in Immunology, 2020, ISSN 1664-3224
Editore: Frontiers Media SA,Frontiers Media S.A.
DOI: 10.3389/fimmu.2020.620312

The Leipzig Health Atlas - An open platform to present, archive and share bio-medical data, analyses and models online

Autori: Toralf Kirsten, Frank A. Meineke, Henry Loeffler-Wirth, Christoph Beger, Alexandr Uciteli, Sebastian Stäubert, Matthias Löbe, René Hänsel, Franziska G. Rauscher, Judith Schuster, Thomas Peschel, Heinrich Herre, Jonas Wagner, Silke Zachariae, Christoph Engel, Markus Scholz, Erhard Rahm, Hans Binder, Markus Loeffler
Pubblicato in: Methods of Information in Medicine, 2022, ISSN 0026-1270
Editore: Schattauer
DOI: 10.1055/a-1914-1985

EnrichIntersect: an R package for custom set enrichment analysis and interactive visualization of intersecting sets

Autori: Zhi Zhao, Manuela Zucknick, Tero Aittokallio
Pubblicato in: Bioinformatics Advances, 2022, ISSN 2635-0041
Editore: Oxford University Press
DOI: 10.1093/bioadv/vbac073

Interleukin-2-induced skin inflammation

Autori: Charline Sommer; Jarish Cohen; Susann Dehmel; Vanessa Neuhaus; Dirk Schaudien, Armin Braun; Katherina Sewald; Michael Rosenblum
Pubblicato in: European Journal of Immunology, 2024, ISSN 1521-4141
Editore: Wiley-VCH GmbH
DOI: 10.1002/eji.202350580

Vascularized patient-derived tumoroids supplemented with immune cells to predict response towards treatment for lung cancer patients

Autori: Hélène Lê; Charlotte Ponté; Jules Desforges; Guoqiang Hua; Ysia Idoux-Gillet; Véronique Lindner; Anne Olland; Pierre-Emanuel Falcoz; Cécile Zaupa; Eric Quéméneur; Jean-Marc Balloul; Nadia Jessel
Pubblicato in: iScience, 2023, ISSN 2589-0042
Editore: Elsevier
DOI: 10.21203/rs.3.rs-2560741/v1

Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology

Autori: Charline Sommer, Sophie Jacob, Tonia Bargmann, Muhammad Shoaib, Basel Alshaikhdeeb, Venkata P. Satagopam, Susann Dehmel, Vanessa Neuhaus, Armin Braun, Katherina Sewald
Pubblicato in: Clinical Immunology, 2024, ISSN 1573-2592
Editore: Springer Nature
DOI: 10.1016/j.clim.2024.110288

Teclistamab impairs detection of BCMA CAR-T cells

Autori: Bettina Glatte; Kerstin Wenk; Anja Grahnert; Maik Friedrich; Maximilian Merz; Vladan Vucinic; Luise Fischer; Kristin Reiche; Miriam Alb; Michael Hudecek; Paul Franz; Stephan Fricke; Uwe Platzbecker; Ulrike Koehl; Ulrich Sack; Andreas Boldt; Sunna Hauschildt; Ronald Weiss
Pubblicato in: Blood Advances, 2023, ISSN 2473-9529
Editore: American Society of Hematology
DOI: 10.1182/bloodadvances.2023009714

Risultati finali

Pubblicazioni

Condividi questa pagina

Scarica